Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | CCR1 | P32246 | 16/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833817 | 1.00 | MAPK14 (0.53) | MAPK14CCR1FPR3GPR65GPR35 | |
| SCHEMBL6502362 | 0.92 | MAPK14 (0.52) | MAPK14CCR1 | |
| SCHEMBL4876597 | 0.92 | MAPK14 (0.54) | MAPK14CCR1FPR3GPR65GPR35 | |
| SCHEMBL4876594 | 0.92 | MAPK14 (0.54) | MAPK14CCR1FPR3GPR65GPR35 | |
| SCHEMBL4830514 | 0.89 | MAPK14 (0.52) | MAPK14CCR1 | |
| SCHEMBL4840029 | 0.84 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL4840023 | 0.84 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL14109708 | 0.84 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL4834276 | 0.81 | MAPK14 (0.44) | MAPK14CCR1 | |
| SCHEMBL4836359 | 0.80 | MAPK14 (0.53) | MAPK14CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | MAPK14 21/4885CCR1 1343/4885FPR3 3612/4885 |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK4 | MAPK14 11/4885CCR1 1632/4885FPR3 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.